Vanda Pharmaceuticals Inc , a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs.
infoVanda Pharmaceuticals is a small cap stock with a total market cap of 338.73M.
infoThey trade on the NASDAQ and had their IPO 17 years and 4 months ago.
infoVanda Pharmaceuticals currently employs 290 people.
infoAs of Wednesday, Aug 23 2023, Vanda Pharmaceuticals’s share price is $5.89.
News Relating to Vanda Pharmaceuticals
PRNewsWire
Vanda Pharmaceuticals to Announce Second Quarter 2023 Financial Results on July 27, 2023
Thursday Jul 20 2023 at 16:30
Conference Call and Webcast to Follow WASHINGTON , July 20, 2023 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2023 on Thursday, July 27, 2023, after the market closes. Vanda will host a conference call at 4:30 PM ET on Thursday, July 27, 2023, during which management will discuss the second quarter 2023 financial results and other corporate activities.
PRNewsWire
Vanda Pharmaceuticals to Announce First Quarter 2023 Financial Results on May 3, 2023
Thursday Apr 27 2023 at 18:00
Conference Call and Webcast to Follow WASHINGTON , April 27, 2023 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the first quarter 2023 on Wednesday, May 3, 2023, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, May 3, 2023, during which management will discuss the first quarter 2023 financial results and other corporate activities.
Seeking Alpha
Vanda Pharmaceuticals Inc. (VNDA) Q4 2022 Earnings Call Transcript
Wednesday Feb 08 2023 at 18:20
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA ) Q4 2022 Earnings Conference Call February 8, 2023 4:30 AM ET Company Participants Kevin Moran – CFO Mihael Polymeropoulos – President, CEO and Chairman Timothy Williams – General Counsel Conference Call Participants Operator Ladies and gentlemen, thank you for standing by, and welcome to the Q4 2022 Vanda Pharmaceuticals Inc. Earnings Conference Call. I would now like to turn the call over to Kevin Moran, Vanda’s Chief Financial Officer.
PRNewsWire
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results on February 8, 2023
Wednesday Feb 01 2023 at 18:30
Conference Call and Webcast to Follow WASHINGTON , Feb. 1, 2023 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and full year 2022 on Wednesday, February 8, 2023, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, February 8, 2023, during which management will discuss the fourth quarter and full year 2022 financial results and other corporate activities.
PRNewsWire
Vanda Pharmaceuticals Announces Participation at November 2022 Investor Conferences
Tuesday Nov 08 2022 at 20:30
WASHINGTON , Nov. 8, 2022 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the following upcoming investor conferences in November 2022: The Stifel 2022 Healthcare Conference on Tuesday, November 15, 2022. A corporate presentation is scheduled for 10:20 a.m.
Seeking Alpha
Vanda Pharmaceuticals Inc. (VNDA) Q3 2022 Earnings Call Transcript
Wednesday Nov 02 2022 at 22:35
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA ) Q3 2022 Earnings Conference Call November 2, 2022 4:30 PM ET Company Participants Kevin Moran – Senior Vice President & Chief Financial Officer Mihael Polymeropoulos – President & Chief Executive Officer Tim Williams – General Counsel Conference Call Participants Operator Good afternoon. My name is Abba and I will be your conference operator today.
Zacks Investment Research
Vanda Pharmaceuticals (VNDA) Lags Q3 Earnings and Revenue Estimates
Wednesday Nov 02 2022 at 18:52
Vanda (VNDA) delivered earnings and revenue surprises of -40% and 8%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
PRNewsWire
Vanda Pharmaceuticals to Announce Third Quarter 2022 Financial Results on November 2, 2022
Wednesday Oct 26 2022 at 18:00
Conference Call and Webcast to Follow WASHINGTON , Oct. 26, 2022 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2022 on Wednesday, November 2, 2022, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, November 2, 2022, during which management will discuss the third quarter 2022 financial results and other corporate activities.
Seeking Alpha
Vanda: VPO-227 Advancement Signals More Upsides
Tuesday Oct 25 2022 at 13:45
From the commercialization front, Vanda Pharmaceuticals is taking prudent steps to boost Hetlioz and Fanapt sales. The company recently planted long-term growth via the OliPas partnership for ASO development.
Seeking Alpha
Vanda Pharmaceuticals: What The Recent Partnership Entails
Thursday Oct 06 2022 at 16:54
Vanda Pharmaceuticals is a stellar growth stock trading near its cash position. Despite the latest revenue trend aberration, Vanda is still set to post significant sales increase for Fiscal 2022.
PRNewsWire
Vanda Pharmaceuticals Announces Participation in the H.C. Wainwright Global Investment Conference
Thursday Sep 08 2022 at 18:00
WASHINGTON , Sept. 8, 2022 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that the company will participate in the H.C.
Business Insider
The latest meme stock rally is fizzling and speculative buying by retail investors will wane through the rest of 2022, says Vanda
Wednesday Aug 24 2022 at 15:40
The latest meme-stock craze was “doomed to wane” partially because investor sentiment is still predominantly bearish, said Vanda Research.
Zacks Investment Research
Vanda Pharmaceuticals (VNDA) Q2 Earnings and Revenues Miss Estimates
Wednesday Aug 03 2022 at 18:48
Vanda (VNDA) delivered earnings and revenue surprises of -54.55% and 3.90%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Seeking Alpha
Vanda Pharmaceuticals Inc. (VNDA) CEO Mihael Polymeropoulos on Q2 2022 Results – Earnings Call Transcript
Wednesday Aug 03 2022 at 18:42
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA ) Q2 2022 Earnings Conference Call August 3, 2022 4:30 PM ET Company Participants Mihael H. Polymeropoulos – President & Chief Executive Officer Kevin Moran – Senior Vice President & Chief Financial Officer Conference Call Participants Chris Howerton – Jefferies Operator Thank you for standing by, and welcome to the Q2 2022 Vanda Pharmaceuticals, Inc. Earnings Call.
PRNewsWire
Vanda Pharmaceuticals to Announce Second Quarter 2022 Financial Results on August 3, 2022
Wednesday Jul 27 2022 at 17:30
Conference Call and Webcast to Follow WASHINGTON , July 27, 2022 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2022 on Wednesday, August 3, 2022, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, August 3, 2022, during which management will discuss the second quarter 2022 financial results and other corporate activities.
PRNewsWire
Vanda Pharmaceuticals Announces Participation in the Jefferies 2022 Global Healthcare Conference
Thursday Jun 02 2022 at 16:30
WASHINGTON , June 2, 2022 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the Jefferies 2022 Global Healthcare Conference in New York City on Thursday, June 9, 2022. A corporate presentation is scheduled for 3:30 p.m.
Seeking Alpha
Vanda Pharmaceuticals: Strong Pipeline Developments To Power Long-Term Upside
Tuesday May 17 2022 at 09:50
I am quite impressed with Vanda Pharmaceuticals’ investing thesis. Though it cooled off recently, Vanda is still positing significant revenues that I expect would leap to a higher level either next year or beyond.
Seeking Alpha
Vanda Pharmaceuticals Inc. (VNDA) CEO Mihael H. Polymeropoulos on Q1 2022 Results – Earnings Call Transcript
Thursday May 05 2022 at 19:07
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Mihael H. Polymeropoulos – President & Chief Executive Officer Kevin Moran – Senior Vice President & Chief Financial Officer Conference Call Participants Operator Ladies and gentlemen, thank you for standing by.
PRNewsWire
Vanda Pharmaceuticals to Announce First Quarter 2022 Financial Results on May 5, 2022
Thursday Apr 28 2022 at 17:00
Conference Call and Webcast to Follow WASHINGTON, April 28, 2022 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the first quarter 2022 on Thursday, May 5, 2022, after the market closes. Vanda will host a conference call at 4:30 PM ET on Thursday, May 5, 2022, during which management will discuss the first quarter 2022 financial results and other corporate activities.
Seeking Alpha
Vanda: A Dual Growth And Value Player
Monday Apr 11 2022 at 14:43
Amid the biotech bear market, many fundamentally sound companies are trading at a fraction of their intrinsic value.
Seeking Alpha
Vanda Pharmaceuticals Inc. (VNDA) CEO Mihael Polymeropoulos on Q4 2021 Results – Earnings Call Transcript
Wednesday Feb 23 2022 at 22:18
Vanda Pharmaceuticals Inc. (VNDA) CEO Mihael Polymeropoulos on Q4 2021 Results – Earnings Call Transcript
PRNewsWire
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022
Thursday Feb 17 2022 at 18:00
WASHINGTON, Feb. 17, 2022 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and full year 2021 on Wednesday, February 23, 2022, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, February 23, 2022, during which management will discuss the fourth quarter and full year 2021 financial results and other corporate activities.
Benzinga
Why Are Vanda Pharma Shares Plunging Today?
Friday Feb 04 2022 at 08:34
Vanda Pharmaceuticals Inc VNDA shares are plunging after the company announced Phase 3 trial data of tradipitant in treating the symptoms of gastroparesis. Get the Inside Access Traders Are Using to Profit More and Win Bigger.
PRNewsWire
Vanda Pharmaceuticals Announces Participation at November 2021 Investor Conferences
Wednesday Nov 10 2021 at 18:30
WASHINGTON, Nov. 10, 2021 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that Vanda management will participate at the following upcoming investor conferences in November 2021: The Stifel 2021 Virtual Healthcare Conference on Monday, November 15, 2021. A corporate presentation is scheduled for 10:00 a.m.
Benzinga
Vanda Pharmaceuticals: Q3 Earnings Insights
Wednesday Nov 03 2021 at 16:41
Vanda Pharmaceuticals (NASDAQ:VNDA) reported its Q3 earnings results on Wednesday, November 3, 2021 at 04:00 PM. Here’s what investors need to know about the announcement.
Benzinga
Vanda Pharmaceuticals Earnings Preview
Tuesday Nov 02 2021 at 11:28
Vanda Pharmaceuticals (NASDAQ:VNDA) is set to give its latest quarterly earnings report on Wednesday, 2021-11-03. Here’s what investors need to know before the announcement.
PRNewsWire
Vanda Pharmaceuticals to Announce Third Quarter 2021 Financial Results on November 3, 2021
Wednesday Oct 27 2021 at 17:30
WASHINGTON, Oct. 27, 2021 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2021 on Wednesday, November 3, 2021, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, November 3, 2021, during which management will discuss the third quarter 2021 financial results and other corporate activities.
PRNewsWire
Vanda Pharmaceuticals Announces Participation at the Citi 16th Annual BioPharma Virtual Conference
Tuesday Sep 07 2021 at 20:30
WASHINGTON, Sept. 7, 2021 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that Vanda’s management will participate at the Citi 16th Annual BioPharma Virtual Conference taking place between September 8 and September 10, 2021.
Zacks Investment Research
Vanda (VNDA) Loses 21.1% in 4 Weeks, Here’s Why a Trend Reversal May be Around the Corner
Thursday Aug 05 2021 at 11:25
Vanda (VNDA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
PRNewsWire
Vanda Pharmaceuticals Closes Enrollment In The ODYSSEY Study Comparing Tradipitant And Placebo In Hospitalized COVID-19 Pneumonia Patients
Tuesday Aug 03 2021 at 07:00
WASHINGTON, Aug. 3, 2021 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that enrollment has closed in the ODYSSEY study comparing tradipitant and placebo in hospitalized COVID-19 pneumonia patients. Enrollment was closed because the study met the pre-defined futility criteria, indicating that the study was unlikely to succeed in its pre-specified primary endpoint.
Vanda Pharmaceuticals Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
Vanda Pharmaceuticals’s Altman Z-score is 2.92 which is in the gray zone. This indicates a level of ambiguity where further analyses are needed to evaluate the company’s financial stability accurately.
Derived from SEC.GOV filing dataopen_in_new
Vanda Pharmaceuticals Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, 1 insider has sold $21.75K of common stock in Vanda Pharmaceuticals on the stock market with no insider buying.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
Vanda Pharmaceuticals’s Income Quality of 4.01 is greater than its Industry Group of 0.69 (481.2% greater)
Vanda Pharmaceuticals’s Income Quality of 4.01 is greater than its Major Industry Group of 0.71 (464.8% greater)
Vanda Pharmaceuticals’s Income Quality of 4.01 is greater than its Sector of 0.75 (434.7% greater)
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
Vanda Pharmaceuticals’s Current Ratio of 6.1 is greater than its Industry Group of 4.76 (28.2% greater)
Vanda Pharmaceuticals’s Current Ratio of 6.1 is greater than its Major Industry Group of 4.32 (41.2% greater)
Vanda Pharmaceuticals’s Current Ratio of 6.1 is greater than its Sector of 2.6 (134.6% greater)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compare a negative PE Ratio (22.73 & -1.27)
Cannot compare a negative PE Ratio (22.73 & -1.1)
Cannot compare a negative PE Ratio (22.73 & -0.4)
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
Vanda Pharmaceuticals’s PB Ratio of 0.63 is lower than its Industry Group of 1.34 (-53.0% lower)
Vanda Pharmaceuticals’s PB Ratio of 0.63 is lower than its Major Industry Group of 1.4 (-55.0% lower)
Vanda Pharmaceuticals’s PB Ratio of 0.63 is lower than its Sector of 1.62 (-61.1% lower)
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
Vanda Pharmaceuticals’s ROE of 0.03 is greater than its Industry Group of -0.44 (106.8% greater)
Vanda Pharmaceuticals’s ROE of 0.03 is greater than its Major Industry Group of -0.38 (107.9% greater)
Vanda Pharmaceuticals’s ROE of 0.03 is greater than its Sector of -0.03 (200.0% greater)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
Vanda Pharmaceuticals’s ROCE of 0.02 is greater than its Industry Group of -0.42 (104.8% greater)
Vanda Pharmaceuticals’s ROCE of 0.02 is greater than its Major Industry Group of -0.37 (105.4% greater)
Vanda Pharmaceuticals’s ROCE of 0.02 is greater than its Sector of -0.04 (150.0% greater)
Derived from SEC.GOV filing dataopen_in_new